The objectives of the Developmental Research Program (DRP) are to continue to renew our innovativescientific endeavors within the DF/HCC Lung Cancer SPORE and to fund efforts that will complement andenhance the overall quality of the DF/HCC Lung Cancer SPORE. The Developmental Research Programwill fund both established and junior investigators as we have in the past.We will set aside $50,000 per year for the Developmental Research Program Awards from SPORE funds.The DF/HCC SPORE has an extensive track record of using institutional funds to support our DevelopmentalResearch Program. This will be supplemented with an additional $250,000 per year in institutional supportas we have in the past. Three to 5 individuals will be awarded each year for as much as two years offunding. The second year of funding will be dependent on making sufficient progress on review by theDevelopmental Research Program. The award will facilitate the research and development of independenceof basic biological science, translational science, and applied science investigators within the DF/HCC LungCancer SPORE program. Thus, candidates will be fellows, postdoctoral fellows, and faculty within thedifferent training programs across the Harvard campus. Success in this Developmental Research ProgramWill be defined as the development of innovative translational science that will generate cancer-relevantinterventions in patients with lung cancer or populations at risk for lung cancer.This program will use the infrastructure created by the Administration, Evaluation and Planning Core to:1. Solicit applications and/or identify novel research projects in the area of lung cancer2. Evaluate these projects for financial and core support3. Fund innovative developmental research projects4. Monitor progress on projects for potential transition into full project status5. Evaluate the program's success in achieving its goals as well as overall SPORE objectives

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090578-06
Application #
7450290
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
6
Fiscal Year
2008
Total Cost
$45,988
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M et al. (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 106:17-21
Rangachari, Deepa; VanderLaan, Paul A; Shea, Meghan et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma. J Thorac Oncol 12:878-883

Showing the most recent 10 out of 263 publications